Exhibit 10.1
June 9, 2025
Connect Biopharm LLC
3580 Carmel Mountain Road, Suite 200
San Diego, California 92130
Cantor Fitzgerald & Co.
110 East 59th Street, 6th floor
New York, New York 10022,
Attention: General Counsel
Email: legal-IBD@cantor.com
with copies to:
Latham & Watkins LLP
12670 High Bluff Drive
San Diego, California 92130
Attention: Michael E. Sullivan
Email: michael.sullivan@lw.com
Davis Polk & Wardwell LLP
900 Middlefield Road
Redwood City, CA 94063
Attention: Emily Roberts
Email: emily.roberts@davispolk.com
Re: Amendment to Sales Agreement
Ladies and Gentlemen:
Reference is hereby made to that certain Sales Agreement, dated as of April 15, 2022 (the “Sales Agreement”), by and among Connect Biopharma Holdings Limited (the “Company”), Leerink Partners LLC (formerly SVB Securities LLC) and Cantor Fitzgerald & Co.
This letter serves as our formal notice of termination of the Sales Agreement solely with respect to Leerink Partners LLC. Pursuant to Section 11(c) of the Sales Agreement, the termination of the Sales Agreement with respect to Leerink Partners LLC will be effective as of the close of business on June 10, 2025. By signing below, the Company hereby agrees to the termination of the Sales Agreement with respect to Leerink Partners LLC effective as of the close of business on June 10, 2025, and permanently and irrevocably waives its right to ten (10) Trading Days’ notice (the “Notice Period”) pursuant to Section 11(c) of the Sales Agreement and any other rights to notice under the Sales Agreement with respect to such termination with respect to Leerink Partners LLC.
[Signature Page Follows]
| Very truly yours, | ||
| LEERINK PARTNERS LLC | ||
| By: | /s/ Peter Fry | |
| Name: Peter Fry | ||
| Title: Head of Alt Equities | ||
| Agreed and Acknowledged: | ||
| CONNECT BIOPHARMA HOLDINGS LIMITED | ||
| By: | /s/ Jeff Cohn | |
| Name: | Jeff Cohn | |
| Title: | General Counsel and Corporate Secretary | |